US OptionsDetailed Quotes
RXRX241206P7000
- 0.10
- -0.15-60.00%
15min DelayClose Dec 4 16:00 ET
0.22High0.05Low
0.22Open0.25Pre Close152 Volume428 Open Interest7.00Strike Price2.42KTurnover92.51%IV3.23%PremiumDec 6, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.3750Delta0.8177Gamma57.04Leverage Ratio-0.0570Theta-0.0001Rho-21.39Eff Leverage0.0019Vega
Recursion Pharmaceuticals Stock Discussion
“The evolution of precision and personalized treatment options for oncology patients provide promising alternatives,” says William McKean, MD, Clinical Investigator at START Mountain Region in Salt Lake City, Utah. “We are so pleased to be working with Recursion as a participating site in the DAHLIA trial, and look forward to advancing the science of cancer treatment.”
$Recursion Pharmaceuticals (RXRX.US)$
$NVIDIA (NVDA.US)$
Goldman Sachs also pointed out in a previous report that by 2025, investors are expected to shift from AI infrastructure to a broader "t...
No comment yet